• Who we are
    • Medicines for Europe
    • Purpose and Objectives
    • OUR VALUES
    • STRUCTURE
    • OUR MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
    • JOB OPPORTUNITIES
  • Key topics
    • COVID-19
    • Access
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • ENVIRONMENT
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • Factsheets
    • Infographics
    • Reports
    • Policy
    • Videos
    • Podcast
  • Newsroom
    • Press releases
    • In the news
    • Press kit
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Who we are
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Who we are
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Environment of value added medicines in Europe
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • Environment of value added medicines in Europe
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • Value Added Medicines award 2019
      • QUOTES
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

What is needed to familiarize oncologists with biosimilar medicines?

11 December 2017

Related Posts

  • Oncology, the new era for biosimilar medicines 8 September 2017 With more than 10 years of positive experience and 700…
  • Biosimilar Medicines for Rheumatologists: Bridging the Gap… 10 June 2016 Over the past decade, biosimilar medicines have generated more than…
  • Health Minister Can Take Action to Increase Patient Access… 8 February 2017 Today, Medicines for Europe engaged alongside its Irish national association…
  • Generic and Biosimilar Medicines Essential for Italian… 8 January 2016 Brussels - Generic and biosimilar medicines represent an essential opportunity to…
Share this
Share on Facebook
Facebook
Share on Google+
Google+
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
Pin on Pinterest
Pinterest
Buffer this page
Buffer
Email this to someone
email
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok